Trending NewsTrending NewsNYSE:DGX Quest Diagnostics (DGX) Stock Price, News & Analysis $228.05 +0.15 (+0.07%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$232.01 +3.96 (+1.74%) As of 07/24/2026 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Quest Diagnostics Stock (NYSE:DGX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Quest Diagnostics alerts:Sign Up Key Stats Today's Range$223.42▼$233.2150-Day Range$189.87▼$228.0552-Week Range$165.78▼$237.78Volume1.54 million shsAverage Volume1.01 million shsMarket Capitalization$25.25 billionP/E Ratio24.21Dividend Yield1.51%Price Target$231.73Consensus RatingModerate Buy Company Overview Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening. Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology. Quest also offers specialized esoteric testing, employer and occupational health testing, clinical trial laboratory services and health information solutions designed to integrate lab data into provider and population health workflows. These capabilities are delivered through laboratory infrastructure, patient collection sites and digital tools that enable ordering, reporting and analytics. Quest primarily serves the United States healthcare market—providing testing and related services to physician practices, hospitals, payers, employers and governmental agencies—while maintaining capabilities that support international clinical trials and diagnostics initiatives. The company has operated for multiple decades and is structured with centralized laboratory operations, regional service locations and an executive leadership team responsible for strategic, clinical and operational oversight.AI Generated. May Contain Errors. Read More Quest Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreDGX MarketRank™: Quest Diagnostics scored higher than 81% of companies evaluated by MarketBeat, and ranked 106th out of 836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingQuest Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 6 buy ratings, 6 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Quest Diagnostics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageQuest Diagnostics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Quest Diagnostics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth5.37% Earnings GrowthEarnings for Quest Diagnostics are expected to grow by 5.37% in the coming year, from $11.17 to $11.77 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quest Diagnostics is 24.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Quest Diagnostics is 24.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.14.Price to Earnings Growth RatioQuest Diagnostics has a PEG Ratio of 2.61. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioQuest Diagnostics has a P/B Ratio of 3.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.20% of the float of Quest Diagnostics has been sold short.Short Interest Ratio / Days to CoverQuest Diagnostics has a short interest ratio ("days to cover") of 4.26.Change versus previous monthShort interest in Quest Diagnostics has recently decreased by 5.98%, indicating that investor sentiment is improving significantly. Dividend4.2 / 5Dividend StrengthStrong Dividend YieldQuest Diagnostics pays a meaningful dividend of 1.51%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthQuest Diagnostics has been increasing its dividend for 14 years.Dividend CoverageThe dividend payout ratio of Quest Diagnostics is 36.52%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 29.23% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.Read more about Quest Diagnostics' dividend. News and Social Media2.4 / 5News Sentiment0.86 News SentimentQuest Diagnostics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 46 news articles for Quest Diagnostics this week, compared to 7 articles on an average week.Search InterestOnly 6 people have searched for DGX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Quest Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Quest Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,570,800.00 in company stock.Percentage Held by Insiders0.88% of the stock of Quest Diagnostics is held by insiders.Percentage Held by Institutions88.06% of the stock of Quest Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Quest Diagnostics' insider trading history. Receive DGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quest Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DGX Stock News HeadlinesQuest Diagnostics (DGX) Stock Gets Fair Value Boost After Q2 Beat And Higher GuidanceJuly 26 at 2:50 AM | finance.yahoo.comWhy Quest Diagnostics (DGX) Is Up 8.2% After Raising 2026 Guidance And Boosting BuybacksJuly 26 at 2:50 AM | finance.yahoo.comUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income Plan - direct ownership in 14 entities controlling U.S. pipelines, terminals, and processing plants, targeting 10% annually. The plan issues 42 payouts per year and is on pace to distribute $53 billion in 2025 - a record. The next distribution drops in days.July 26 at 1:00 AM | Freedom Financial (Ad)Robert W. Baird Increases Quest Diagnostics (NYSE:DGX) Price Target to $255.00July 26 at 2:08 AM | americanbankingnews.comMizuho Forecasts Strong Price Appreciation for Quest Diagnostics (NYSE:DGX) StockJuly 26 at 1:18 AM | americanbankingnews.comQuest Diagnostics (NYSE:DGX) Price Target Raised to $250.00 at Truist FinancialJuly 25 at 4:37 AM | americanbankingnews.comQuest Diagnostics (NYSE:DGX) Hits New 52-Week High on Better-Than-Expected EarningsJuly 25 at 1:20 AM | americanbankingnews.comQuest Diagnostics Surges After Hims- And Oura-Tied BeatJuly 24 at 10:11 PM | investors.comSee More Headlines DGX Stock Analysis - Frequently Asked Questions How have DGX shares performed this year? Quest Diagnostics' stock was trading at $173.47 at the beginning of the year. Since then, DGX stock has increased by 31.5% and is now trading at $228.0520. How were Quest Diagnostics' earnings last quarter? Quest Diagnostics Incorporated (NYSE:DGX) announced its quarterly earnings data on Thursday, July, 23rd. The medical research company reported $3.12 EPS for the quarter, beating the consensus estimate of $2.82 by $0.30. The firm's revenue for the quarter was up 10.2% compared to the same quarter last year. Read the conference call transcript. How will Quest Diagnostics' stock buyback program work? Quest Diagnostics' Board of Directors approved a stock repurchase program on Tuesday, February 10th 2026, which allows the company to repurchase $1,000,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 4.7% of its stock through open market purchases. Stock buyback programs are often a sign that the company's management believes its stock is undervalued. Does Quest Diagnostics have any subsidiaries? Quest Diagnostics subsidiaries include these companies: MACL, Blueprint Genetics, PhenoPath Laboratories, ReproSource, California Laboratory Associates, Cleveland HeartLab, Cape Cod Healthcare - Business, and others. When did Quest Diagnostics IPO? Quest Diagnostics (DGX) raised $12 million in an initial public offering (IPO) on Tuesday, January 7th 2025. The company issued 2,300,000 shares at $4.00-$6.00 per share. Dominari Securities and Revere Securities acted as the underwriters for the IPO. Who are Quest Diagnostics' major shareholders? Top institutional investors of Quest Diagnostics include Eastern Bank (0.17%), JGP Wealth Management LLC (0.06%), Handelsbanken Fonder AB (0.03%) and Czech National Bank (0.03%). Insiders that own company stock include J E Davis, Catherine T Doherty, Michael E Prevoznik, Michael J Deppe, Gary M Pfeiffer, Vicky B Gregg, Patrick Plewman, Karthik Kuppusamy and Mark E Delaney. View institutional ownership trends. How do I buy shares of Quest Diagnostics? Shares of DGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quest Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quest Diagnostics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), GE Aerospace (GE) and ServiceNow (NOW). Company Calendar Record date for 7/22 Dividend7/08/2026Ex-Dividend for 7/22 Dividend7/08/2026Dividend Payable7/22/2026Last Earnings7/23/2026Today7/26/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 DGX's financial health is in the Green zone, according to TradeSmith. DGX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - OUTP/HM CRE Sub-IndustryHealth Care Services Current SymbolNYSE:DGX CIK1022079 Webwww.questdiagnostics.com Phone(973) 520-2700Fax201-462-4169Employees57,000Year Founded1967Price Target and Rating Average Price Target for Quest Diagnostics$231.73 High Price Target$260.00 Low Price Target$200.00 Potential Upside/Downside+1.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)$9.42 Trailing P/E Ratio24.21 Forward P/E Ratio20.42 P/E Growth2.61Net Income$992 million Net Margins9.18% Pretax Margin12.15% Return on Equity16.01% Return on Assets7.27% Debt Debt-to-Equity Ratio0.72 Current Ratio1.59 Quick Ratio1.08 Sales & Book Value Annual Sales$11.04 billion Price / Sales2.29 Cash Flow$15.18 per share Price / Cash Flow15.02 Book Value$70.64 per share Price / Book3.23Miscellaneous Outstanding Shares110,700,000Free Float109,722,000Market Cap$25.25 billion OptionableOptionable Beta0.58 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NYSE:DGX) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersThe comeback story of the century (ticker inside)In 2013, this struggling PC maker went private amid skepticism from Forbes and the New York Times. Instead of ...InvestorPlace | SponsoredUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...Brownstone Research | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredThe 90%-off options that empty accountsA call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...Profits Run | SponsoredHave you seen Elon’s new “supercurrency”? (It affects you)Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quest Diagnostics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Quest Diagnostics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
